nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Obstruction—Cyclosporine—focal segmental glomerulosclerosis	0.12	0.12	CcSEcCtD
Methylphenidate—Hallucination, visual—Cyclosporine—focal segmental glomerulosclerosis	0.0432	0.0432	CcSEcCtD
Methylphenidate—Stomach ache—Cyclosporine—focal segmental glomerulosclerosis	0.0265	0.0265	CcSEcCtD
Methylphenidate—Thrombocytopenic purpura—Cyclosporine—focal segmental glomerulosclerosis	0.024	0.024	CcSEcCtD
Methylphenidate—Ear disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0209	0.0209	CcSEcCtD
Methylphenidate—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.0179	0.0179	CcSEcCtD
Methylphenidate—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0174	0.0174	CcSEcCtD
Methylphenidate—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.0146	0.0146	CcSEcCtD
Methylphenidate—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.0144	0.0144	CcSEcCtD
Methylphenidate—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.0143	0.0143	CcSEcCtD
Methylphenidate—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.0124	0.0124	CcSEcCtD
Methylphenidate—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.0113	0.0113	CcSEcCtD
Methylphenidate—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.0104	0.0104	CcSEcCtD
Methylphenidate—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.0103	0.0103	CcSEcCtD
Methylphenidate—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.0102	0.0102	CcSEcCtD
Methylphenidate—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.0101	0.0101	CcSEcCtD
Methylphenidate—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.00983	0.00983	CcSEcCtD
Methylphenidate—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00978	0.00978	CcSEcCtD
Methylphenidate—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00959	0.00959	CcSEcCtD
Methylphenidate—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00941	0.00941	CcSEcCtD
Methylphenidate—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00937	0.00937	CcSEcCtD
Methylphenidate—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00923	0.00923	CcSEcCtD
Methylphenidate—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.00915	0.00915	CcSEcCtD
Methylphenidate—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00911	0.00911	CcSEcCtD
Methylphenidate—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.00907	0.00907	CcSEcCtD
Methylphenidate—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.0089	0.0089	CcSEcCtD
Methylphenidate—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00883	0.00883	CcSEcCtD
Methylphenidate—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.00875	0.00875	CcSEcCtD
Methylphenidate—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00871	0.00871	CcSEcCtD
Methylphenidate—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00867	0.00867	CcSEcCtD
Methylphenidate—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.00864	CcSEcCtD
Methylphenidate—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00839	0.00839	CcSEcCtD
Methylphenidate—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00835	0.00835	CcSEcCtD
Methylphenidate—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00812	0.00812	CcSEcCtD
Methylphenidate—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00806	0.00806	CcSEcCtD
Methylphenidate—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00806	0.00806	CcSEcCtD
Methylphenidate—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00775	0.00775	CcSEcCtD
Methylphenidate—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00748	0.00748	CcSEcCtD
Methylphenidate—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0074	0.0074	CcSEcCtD
Methylphenidate—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00737	0.00737	CcSEcCtD
Methylphenidate—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00724	0.00724	CcSEcCtD
Methylphenidate—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00694	0.00694	CcSEcCtD
Methylphenidate—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.0068	0.0068	CcSEcCtD
Methylphenidate—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00678	0.00678	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00657	0.00657	CcSEcCtD
Methylphenidate—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00644	0.00644	CcSEcCtD
Methylphenidate—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.0064	0.0064	CcSEcCtD
Methylphenidate—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00634	0.00634	CcSEcCtD
Methylphenidate—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00631	0.00631	CcSEcCtD
Methylphenidate—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00631	0.00631	CcSEcCtD
Methylphenidate—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00629	0.00629	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00622	0.00622	CcSEcCtD
Methylphenidate—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00618	0.00618	CcSEcCtD
Methylphenidate—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00613	0.00613	CcSEcCtD
Methylphenidate—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00601	0.00601	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00597	0.00597	CcSEcCtD
Methylphenidate—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00595	0.00595	CcSEcCtD
Methylphenidate—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00592	0.00592	CcSEcCtD
Methylphenidate—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00569	0.00569	CcSEcCtD
Methylphenidate—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00568	0.00568	CcSEcCtD
Methylphenidate—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00566	0.00566	CcSEcCtD
Methylphenidate—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00562	0.00562	CcSEcCtD
Methylphenidate—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00559	0.00559	CcSEcCtD
Methylphenidate—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00556	0.00556	CcSEcCtD
Methylphenidate—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00555	0.00555	CcSEcCtD
Methylphenidate—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00546	0.00546	CcSEcCtD
Methylphenidate—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00525	0.00525	CcSEcCtD
Methylphenidate—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00514	0.00514	CcSEcCtD
Methylphenidate—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0051	0.0051	CcSEcCtD
Methylphenidate—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00508	0.00508	CcSEcCtD
Methylphenidate—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00506	0.00506	CcSEcCtD
Methylphenidate—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.005	0.005	CcSEcCtD
Methylphenidate—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00496	0.00496	CcSEcCtD
Methylphenidate—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00493	0.00493	CcSEcCtD
Methylphenidate—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00484	0.00484	CcSEcCtD
Methylphenidate—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00479	0.00479	CcSEcCtD
Methylphenidate—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00474	0.00474	CcSEcCtD
Methylphenidate—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00465	0.00465	CcSEcCtD
Methylphenidate—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00462	0.00462	CcSEcCtD
Methylphenidate—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00457	0.00457	CcSEcCtD
Methylphenidate—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00456	0.00456	CcSEcCtD
Methylphenidate—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00453	0.00453	CcSEcCtD
Methylphenidate—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.0045	0.0045	CcSEcCtD
Methylphenidate—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00444	0.00444	CcSEcCtD
Methylphenidate—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00443	0.00443	CcSEcCtD
Methylphenidate—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00441	0.00441	CcSEcCtD
Methylphenidate—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.0043	0.0043	CcSEcCtD
Methylphenidate—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00427	CcSEcCtD
Methylphenidate—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00426	0.00426	CcSEcCtD
Methylphenidate—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.0042	0.0042	CcSEcCtD
Methylphenidate—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.0042	0.0042	CcSEcCtD
Methylphenidate—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.0042	0.0042	CcSEcCtD
Methylphenidate—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00418	0.00418	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00417	0.00417	CcSEcCtD
Methylphenidate—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00415	0.00415	CcSEcCtD
Methylphenidate—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.0041	0.0041	CcSEcCtD
Methylphenidate—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00406	0.00406	CcSEcCtD
Methylphenidate—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00402	0.00402	CcSEcCtD
Methylphenidate—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00402	0.00402	CcSEcCtD
Methylphenidate—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.004	0.004	CcSEcCtD
Methylphenidate—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.00394	CcSEcCtD
Methylphenidate—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.00394	CcSEcCtD
Methylphenidate—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00391	0.00391	CcSEcCtD
Methylphenidate—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00389	0.00389	CcSEcCtD
Methylphenidate—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00383	0.00383	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00366	0.00366	CcSEcCtD
Methylphenidate—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00364	0.00364	CcSEcCtD
Methylphenidate—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00361	0.00361	CcSEcCtD
Methylphenidate—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00359	0.00359	CcSEcCtD
Methylphenidate—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00358	0.00358	CcSEcCtD
Methylphenidate—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00354	0.00354	CcSEcCtD
Methylphenidate—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.0035	0.0035	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00347	0.00347	CcSEcCtD
Methylphenidate—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00347	0.00347	CcSEcCtD
Methylphenidate—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00344	0.00344	CcSEcCtD
Methylphenidate—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00344	0.00344	CcSEcCtD
Methylphenidate—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00331	0.00331	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.00329	CcSEcCtD
Methylphenidate—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.0032	0.0032	CcSEcCtD
Methylphenidate—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.00318	CcSEcCtD
Methylphenidate—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.00318	CcSEcCtD
Methylphenidate—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00296	CcSEcCtD
Methylphenidate—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.00289	CcSEcCtD
Methylphenidate—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00285	0.00285	CcSEcCtD
Methylphenidate—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00275	0.00275	CcSEcCtD
Methylphenidate—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00266	CcSEcCtD
Methylphenidate—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00256	0.00256	CcSEcCtD
Methylphenidate—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00254	0.00254	CcSEcCtD
Methylphenidate—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00253	0.00253	CcSEcCtD
Methylphenidate—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00252	0.00252	CcSEcCtD
Methylphenidate—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.00239	CcSEcCtD
